

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

SPACE FOR PHARMACODE

foodstuff components (phytin, oxalates, tannin, etc.) and concomitant administration of medicaments (tetracyclines, antacids) is unlikely to occur. Saferon Syrup does not cause teeth staining. The haemoccult-test (selective for haemoglobin) for the detection of occult blood is not impaired and therefore iron therapy must not be interrupted. Recommended dosage Dosage and duration of therapy are dependent upon the extent of iron deficiency. The daily dose can be divided into separate doses or can be taken at one time. Saferon Syrup should be taken during or immediately after a meal. In cases of manifest iron deficiency the therapy takes 3 - 5 months until a normalisation of the haemoglobin value is achieved. Afterwards the therapy should be continued for several weeks with a dosage such as described for latent iron deficiency to replenish the iron stores.																	
<table border="1"> <thead> <tr> <th>Saferon</th><th>Manifestation of iron deficiency</th><th>Latent iron deficiency</th></tr> </thead> <tbody> <tr> <td>Infants (upto 1 year)</td><td>2.5 - 5 ml daily</td><td></td></tr> <tr> <td>Children (1-12 years)</td><td>5 - 10 ml daily</td><td>2.5 - 5 ml daily</td></tr> <tr> <td>Children (>12 years) adults and nursing women</td><td>10 - 20 ml daily</td><td>5 - 10 ml daily</td></tr> <tr> <td>Pregnant women</td><td>20-30 ml daily</td><td>10 ml daily</td></tr> </tbody> </table>			Saferon	Manifestation of iron deficiency	Latent iron deficiency	Infants (upto 1 year)	2.5 - 5 ml daily		Children (1-12 years)	5 - 10 ml daily	2.5 - 5 ml daily	Children (>12 years) adults and nursing women	10 - 20 ml daily	5 - 10 ml daily	Pregnant women	20-30 ml daily	10 ml daily
Saferon	Manifestation of iron deficiency	Latent iron deficiency															
Infants (upto 1 year)	2.5 - 5 ml daily																
Children (1-12 years)	5 - 10 ml daily	2.5 - 5 ml daily															
Children (>12 years) adults and nursing women	10 - 20 ml daily	5 - 10 ml daily															
Pregnant women	20-30 ml daily	10 ml daily															
Overdosage In case of overdose neither intoxication nor iron overload have been reported. Dosage forms available & strength Syrup: 50mg/5ml Chewable Tablets: 100mg/tablet Storage conditions Store below 30°C. Protect from light. Shelf life 30 months Pack size A Bottle of 150 ml MAL06021261XZ Date of Revision: 1 October 2018																	
Product Registration Holder: Glenmark Pharmaceuticals (Malaysia) Sdn Bhd (660397-W) D-31-02, Menara Suezcap 1, No. 2, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia Manufactured by: glenmark PHARMACEUTICALS LTD. Plot No. E-37, 39, MIDC Area, Satpur, Nasik - 422 007, Maharashtra, India. © Registered Trade Mark																	
		MY 0000 PE0000															

PANTONE SHADE
 PANTONE BLACK PROCESS C
Supersedes Artwork Code

PHARMACODE: